Real-life persistence of golimumab in patients with chronic inflammatory rheumatic diseases: results of the 2-year observational GO-PRACTICE study
Résumé
Objective GO-PRACTICE aimed to evaluate the persistence, clinical response and safety of golimumab in adult patients with chronic inflammatory rheumatic disease. Methods Prospective observational study with 24 months of follow-up, involving 134 rheumatologists from public or private health establishments in France. The primary outcome was the persistence of golimumab 24 months after initial prescription. Cumulative persistence probabilities were determined from Kaplan-Meier estimates. Secondary outcomes included an evaluation of disease activity and golimumab safety profile.
Fichier principal
Flipo et al. - 2020 - Real-life persistence of golimumab in patients wit.pdf (796.49 Ko)
Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte